• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Teleflex Incorporated

    5/29/25 10:58:02 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email
    SD 1 tfx2025-formsd.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM SD
    Specialized Disclosure Report

    TELEFLEX INCORPORATED
    (Exact name of registrant as specified in its charter)

    Delaware1-535323-1147939
    (State or Other Jurisdiction of
    Incorporation or Organization)
    (Commission
    File Number)
    I.R.S Employer
    Identification Number


    550 E. Swedesford Road, Suite 400, Wayne, Pennsylvania19087
    (Address of Principal Executive Offices)(Zip Code)

    James Winters, Corporate Vice President, Manufacturing and Supply Chain (610) 225-6800
    (Name and telephone number, including area code, of the person to contact in connection with this report.)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐
    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended____.





    Section 1 - Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    The disclosures required by this item are included in the Conflict Minerals Report of Teleflex Incorporated (the “Company”), which is filed as Exhibit 1.01 to this Form SD and is publicly available under the “Investors - SEC Filings” section of the Company’s website at www.teleflex.com.

    Item 1.02 Exhibit

    The Company’s Conflict Minerals Report is filed as Exhibit 1.01 to this Form SD.

    Section 2 - Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Note applicable

    Section 3 - Exhibits

    Item 3.01 Exhibits

    Exhibit 1.01 - Conflict Minerals Report for the reporting period from January 1, 2024 to December 31, 2024.






    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    Date: May 29, 2025  TELEFLEX INCORPORATED
      By: /s/ James Winters
       Name: James Winters
       Title: 
    Corporate Vice President, Manufacturing and Supply Chain


    Get the next $TFX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Teleflex downgraded by BofA Securities with a new price target

      BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

      3/4/25 7:44:32 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

      2/28/25 7:34:55 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by Raymond James

      Raymond James downgraded Teleflex from Outperform to Mkt Perform

      2/28/25 7:34:03 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

      WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication. On Febr

      7/1/25 6:30:13 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

      WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.70.5% reduction in the incidence of CLABSI in patien

      6/12/25 6:29:59 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men's Health Month

      Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment.   WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading globa

      6/11/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duncan Candace H was granted 1,051 shares, increasing direct ownership by 22% to 5,907 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:30 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Patil Neena M was granted 1,051 shares, increasing direct ownership by 67% to 2,626 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:06 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Heinmiller John C was granted 1,051 shares, increasing direct ownership by 34% to 4,176 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:20 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    SEC Filings

    See more
    • SEC Form 11-K filed by Teleflex Incorporated

      11-K - TELEFLEX INC (0000096943) (Filer)

      6/27/25 2:33:24 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Teleflex Incorporated

      SD - TELEFLEX INC (0000096943) (Filer)

      5/29/25 10:58:02 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Incorporated filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TELEFLEX INC (0000096943) (Filer)

      5/15/25 4:06:35 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

      WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

      2/27/25 6:36:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Financials

    Live finance-specific insights

    See more
    • Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

      WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication. On Febr

      7/1/25 6:30:13 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

      WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan

      5/1/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/14/24 1:28:29 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/8/24 10:29:30 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      2/14/24 10:04:36 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care